Cipher Pharmaceuticals Inc.
CPH.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 49.62M | 50.94M | 50.45M | 50.06M | 47.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.62M | 50.94M | 50.45M | 50.06M | 47.59M |
| Cost of Revenue | 9.23M | 9.36M | 10.03M | 12.85M | 12.48M |
| Gross Profit | 40.40M | 41.58M | 40.42M | 37.20M | 35.12M |
| SG&A Expenses | 13.47M | 14.38M | 16.30M | 17.47M | 18.36M |
| Depreciation & Amortization | 7.20M | 7.22M | 7.23M | 6.94M | 7.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.89M | 30.95M | 33.59M | 37.28M | 37.92M |
| Operating Income | 19.73M | 19.99M | 16.87M | 12.77M | 9.67M |
| Income Before Tax | 17.46M | 20.23M | 17.16M | 9.70M | 5.76M |
| Income Tax Expenses | -11.52M | -10.64M | -10.17M | -7.67M | -6.38M |
| Earnings from Continuing Operations | 28.99 | 30.87 | 27.33 | 17.36 | 12.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.99M | 30.87M | 27.33M | 17.36M | 12.14M |
| EBIT | 19.73M | 19.99M | 16.87M | 12.77M | 9.67M |
| EBITDA | 26.48M | 26.84M | 23.81M | 19.53M | 16.56M |
| EPS Basic | 1.14 | 1.21 | 1.07 | 0.68 | 0.47 |
| Normalized Basic EPS | 0.44 | 0.50 | 0.42 | 0.26 | 0.20 |
| EPS Diluted | 1.11 | 1.18 | 1.04 | 0.66 | 0.46 |
| Normalized Diluted EPS | 0.43 | 0.48 | 0.41 | 0.25 | 0.20 |
| Average Basic Shares Outstanding | 101.66M | 102.13M | 102.13M | 102.25M | 102.05M |
| Average Diluted Shares Outstanding | 103.84M | 104.36M | 104.76M | 104.38M | 104.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |